LITHOBID® (lithium carbonate)
is an extended-release formulation containing 300mg of lithium carbonate. LITHOBID is indicated
in the treatment of manic episodes of Bipolar
Disorder. Bipolar Disorder, Manic (DSM-IV) is
equivalent to Manic Depressive illness, Manic,
in the older DSM-II terminology. LITHOBID is
also indicated as a maintenance treatment for
individuals with a diagnosis of Bipolar Disorder.
Maintenance therapy reduces the frequency of
manic episodes and diminishes the intensity of
those episodes which may occur.
Important Notice:
The LITHOBID ® (lithium carbonate) Patient Assistance Program is ending December 31, 2009. Click Here for more information.
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.